Artelo Biosciences (NASDAQ:ARTL) Receives Buy Rating from HC Wainwright

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 400.00% from the company’s previous close.

Several other research firms have also recently weighed in on ARTL. D. Boral Capital restated a “buy” rating and issued a $6.00 price objective on shares of Artelo Biosciences in a research report on Thursday, February 27th. LADENBURG THALM/SH SH raised shares of Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th.

Artelo Biosciences Price Performance

ARTL stock opened at $1.00 on Tuesday. The business has a fifty day moving average price of $1.16 and a 200 day moving average price of $1.16. Artelo Biosciences has a fifty-two week low of $0.91 and a fifty-two week high of $1.70. The stock has a market capitalization of $3.23 million, a price-to-earnings ratio of -0.35 and a beta of 1.25.

Artelo Biosciences (NASDAQ:ARTL) last announced its earnings results on Monday, March 3rd. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.43). On average, equities analysts expect that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.